Hepatitis B infection is caused by the hepatitis B virus (HBV), an enveloped DNA virus that infects the liver, causing hepatocellular necrosis and inflammation. HBV infection can be either acute or chronic, and the associated illness ranges in severity from asymptomatic to symptomatic, progressive disease. Chronic hepatitis B (CHB) – defined as persistence of hepatitis B surface antigen (HBsAg) for six months or more – is a major public health problem. Worldwide, there are an estimated 240 million chronically infected persons, particularly in low- and middle-income countries (LMICs). The major complications of CHB are cirrhosis and hepatocellular carcinoma (HCC). Between 20% and 30% of those who become chronically infected will develop these complications, and an estimated 650 000 people will die annually due to CHB. The majority of people are unaware of their HBV infection, and therefore often present with advanced disease. Universal hepatitis B immunization programmes that target infants, with the first dose at birth, have been highly effective in reducing the incidence and prevalence of hepatitis B in many endemic countries. However, these programmes will not have an impact on HBV-related deaths until several decades after their introduction.
2015年WHO慢性乙型肝炎感染患者的预防、护理和治疗指南
发布日期:2015-01-03
英文标题:Guidelines for the prevention, care and treatment of persons with chronic hepatitis B infection
来源:WHO官网
阅读次数:1705
相关指南
- 2014年美国胃肠病学会指南:免疫抑制剂治疗过程中HBV再激活的预防及治疗
- 政策简报:慢性乙型肝炎病毒感染预防、关怀和治疗指南(2015年3月)
- 替诺福韦酯治疗慢性HBV感染临床应用专家共识
- 2015年WGO全球指南:乙型肝炎(V2.0)
- 慢性乙型肝炎特殊患者抗病毒治疗专家共识:2015年更新
- 2015年WHO慢性乙型肝炎感染患者的预防、护理和治疗指南
- 2014年中国慢性乙型肝炎防治指南(科普版)
- 2014年美国胃肠病学会免疫抑制治疗中HBV再激活防治指南
- 2014年SIMIT意见书:急性乙型肝炎的管理
- 核苷和核苷酸类药物治疗慢性乙型肝炎的长期性
- 2013 版英国《儿童、青年和成人慢性乙型肝炎诊断和管理指南》解读